Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Our report is an authoritative Owner’s Manual on the company.
- A vital piece in the investor’s toolbox, our report allows you to uncover the essence of the business
- We pinpoint strengths and weaknesses; discuss strategy
- Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue

We offer our research as a service for Japanese corporates.
- Our in-depth reports allow them to better inform investors by presenting an unbiased third-party view of business fundamentals
- Our reports do not offer investment opinions and are free for all investors

We start our coverage with a substantial core report.
- We continuously update this report to reflect earnings, news flow, and any material developments
- We thoroughly interview management on a quarterly basis

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>MEDINET's sales increased by 2.3% YoY to JPY414mn, with an operating loss of JPY630mn and net loss of JPY551mn.</li><li>CDMO business sales grew 118.4% YoY to JPY112mn, driven by technology transfer fees and cost-cutting efforts.</li><li>Regenerative Medicinal Product Business reported no sales, with a segment loss of JPY279mn, and development plans for Stempeucel® and NeoCart®.</li></ul>

MEDINET's sales increased by 2.3% YoY to JPY414mn, with an operating loss of JPY630mn and net loss of JPY551mn.CDMO business sales grew 118.4% YoY to JPY112mn, driven by technology transfer fees and cost-cutting efforts.Regenerative Medicinal Product Business reported no sales, with a segment loss of JPY279mn, and development plans for Stempeucel® and NeoCart®.

メディネット株式会社（2370 JP）：2009/26年度上半期速報

Medinet Co Ltd

メディネット株式会社（2370 JP）：2009/26年度上半期速報